Optimization of treatment tactics in patients with abnormal uterine bleeding on the background of benign hyperplastic processes in the uterus

Aim. Optimization of management tactics for patients with abnormal uterine bleeding on the background of benign endometrial and myometrial hyperplastic processes (BEMH) using systemic enzyme therapy. Materials and methods. 90 female patients with BEMH were included. They were divided into three groups: group 1 - women with endometrial hyperplasia, group 2 - women with uterine myoma of small size (6-8 weeks) in combination with endometrial hyperplasia and group 3 - women with endometrial hyperplasia in combination with endometriosis. Systemic enzyme therapy drug was used. Results and conclusions. BEMH are accompanied by inhibition of cellular immunity (pronounced suppression of T-lymphocytes) and excessive activation of humoral immunity. Therefore, an immunomodulatory effect of systemic enzyme therapy at hyperplastic processes is the basis for its prescription for comprehensive treatment of patients with combined endometrial and myometrial hyperplastic processes.

abnormal uterine bleeding, benign endometrial and myometrial hyperplastic processes, systemic enzyme therapy